MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Evotec AG

Open

SectorFinanciën

5.95 0.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.75

Max

6.08

Belangrijke statistieken

By Trading Economics

Inkomsten

55M

-40M

Verkoop

2.8M

185M

Winstmarge

-21.437

Werknemers

5,007

EBITDA

58M

-45M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+116.95% upside

Dividenden

By Dow Jones

Volgende Winsten

17 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.1B

Vorige openingsprijs

5.61

Vorige sluitingsprijs

5.95

Nieuwssentiment

By Acuity

27%

73%

89 / 542 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Evotec AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jun 2024, 13:17 UTC

Marktinformatie

Evotec's Profit Outlook Looks Gloomy -- Market Talk

Peer Vergelijking

Prijswijziging

Evotec AG Prognose

Koersdoel

By TipRanks

116.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12.8 EUR  116.95%

Hoogste 14 EUR

Laagste 11.6 EUR

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Evotec AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technische score

By Trading Central

5.76 / 6.075Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

89 / 542 Rangschikking in Financiën

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.